ACAD
31.07
-0.15
-0.48%
AEMD
0.25
-0.01
-4.48%
APRI
1.42
+0.09
+6.99%
ARNA
4.5
-0.06
-1.32%
ATEC
1.3
0.00
0.00%
CFN
59.59
+0.03
+0.04%
CNAT
5.98
+0.19
+3.28%
CRXM
0.21
0.00
0.00%
CYTX
0.48
0.00
0.00%
DXCM
61
+0.41
+0.68%
GNMK
13.3
+0.19
+1.45%
HALO
14.59
+0.44
+3.07%
ILMN
200.01
+2.15
+1.09%
INNV
0.21
+0.01
+4.95%
INO
8.5
0.00
0.00%
ISCO
0.06
+0.00
+7.83%
ISIS
69.88
+1.3
+1.90%
LGND
56.88
-0.54
-0.94%
LPTN
2.79
-0.1
-3.46%
MBVX
1.05
-0.1
-8.70%
MEIP
3.84
+0.12
+3.23%
MNOV
3.8
+0.01
+0.26%
MRTX
21.34
+0.88
+4.30%
MSTX
0.43
-0.02
-3.98%
NBIX
34.29
+0.9
+2.70%
NUVA
47.28
+0.81
+1.74%
ONCS
0.37
-0.02
-5.19%
ONVO
6.68
+0.19
+2.93%
OREX
5.34
-0.16
-2.82%
OTIC
31.75
+0.02
+0.06%
QDEL
24.45
+0.09
+0.37%
RCPT
112.71
-0.36
-0.32%
RGLS
18.63
+0.97
+5.49%
RMD
63.09
-0.23
-0.36%
SCIE
0.01
0.00
-9.60%
SPHS
0.47
+0.03
+6.59%
SRNE
10.73
+0.34
+3.27%
TROV
5.83
-0.02
-0.34%
VICL
1.05
+0.02
+1.46%
VOLC
17.98
+0.02
+0.11%
ZGNX
1.37
-0.02
-1.09%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee

January 20, 2015 – 3:02 pm | Edit Post
Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee

SAN DIEGO and TORONTO, Jan. 20, 2015 /PRNewswire/ – Aptose Biosciences Inc.
(NASDAQ: APTO, TSX: APS), a clinical-stage company developing new
therapeutics and molecular diagnostics that target the underlying
mechanisms of cancer, announced today that Dr. Bradley Thompson has
been appointed to the Audit Committee, and that the NASDAQ Stock Market
(“NASDAQ”) has notified the Company it has regained compliance with
Listing Rule 5605 to maintain three independent members on the Audit
Committee.

On December 15, 2014, Dr. Brian Underdown, a member of the Board of
Directors and Audit Committee, resigned from the Aptose Board of
Directors in conjunction with the appointment of Dr. Erich Platzer to
the Board. This left the Audit Committee with only two independent
members until Dr. Bradley Thompson was formally appointed to the
committee. As previously reported on January 15, 2015 in the Company’s
6K filing with the Securities and Exchange Commission, on January 13,
2015
the Company received, as expected, a notification letter from
NASDAQ stating that the Company no longer complied with NASDAQ’s audit
committee requirements of maintaining committee membership by at least
three independent directors as set forth in Listing Rule 5605 due to
the resignation of Dr. Brian Underdown,  which was previously reported
on December 15, 2014, in its Form 6-K filing with the Securities and
Exchange Commission. The NASDAQ letter was issued in accordance with
standard NASDAQ procedures.

Consistent with Listing Rule 5605(c)(4), NASDAQ provided the Company a
cure period in order to regain compliance as follows:

  • until the earlier of the Company’s next annual shareholders’ meeting or
    December 15, 2015; or
  • if the next annual shareholders’ meeting is held before June 15, 2015,
    then the Company must evidence compliance no later than June 15, 2015.

On January 16, 2015 the Company appointed Dr. Bradley Thompson to the
Audit Committee and was notified by NASDAQ today that the Company has
regained compliance with Listing Rule 5605.

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed
to discovering and developing personalized therapies that address unmet
medical needs in oncology. Aptose is advancing new therapeutics focused
on novel cellular targets on the leading edge of cancer research
coupled with companion diagnostics to identify the optimal patient
population for its products. Aptose’s lead anticancer agent APTO-253 is
under development for AML, MDS and other hematologic malignancies. For
further information, please visit www.aptosebiosciences.com.

Forward Looking Statements

This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include,
but are not limited to, statements relating to the Company’s plans,
objectives, expectations and intentions and other statements including
words such as “continue”, “expect”, “intend”, “will”, “should”,
“would”, “may”, and other similar expressions. Such statements reflect
our current views with respect to future events and are subject to
risks and uncertainties and are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by us are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements described in this press release. Such expressed or implied
forward looking statements could include, among others: our ability to
obtain the capital required for research and operations; the inherent
risks in early stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the progress
of our clinical trials; our ability to find and enter into agreements
with potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed from
time-to-time in our ongoing quarterly filings, annual information
forms, annual reports and annual filings with Canadian securities
regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or
should the assumptions set out in the section entitled “Risk Factors”
in our filings with Canadian securities regulators and the United
States Securities and Exchange Commission underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this press release and we do not
intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure
you that such statements will prove to be accurate as actual results
and future events could differ materially from those anticipated in
such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on forward-looking
statements due to the inherent uncertainty therein.

SOURCE Aptose Biosciences Inc.

Arena Pharmaceuticals Announces Public Offering of Common Stock

January 20, 2015 – 2:04 pm | Edit Post
Arena Pharmaceuticals Announces Public Offering of Common Stock

SAN DIEGO, Jan. 20, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares are being offered by Arena.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering. 

A registration statement relating to the shares described above was previously filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Arena Pharmaceuticals

Arena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena’s internally discovered drug, BELVIQ® (lorcaserin HCl), is approved in the United States, and Arena is focused on discovering, developing and commercializing additional drugs to address unmet medical needs. Arena’s US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena’s expectations with respect to the public offering; embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena’s focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks and uncertainties related to the public offering, including the satisfaction of customary closing conditions; risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena’s revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena’s guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena’s business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena’s research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena’s and third parties’ intellectual property rights; the timing, success and cost of Arena’s research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo Partners

Craig M. Audet, Ph.D., Senior Vice President,

Operations & Head of Global Regulatory Affairs

caudet@arenapharm.com

858.453.7200, ext. 1612

David Schull, President

david.schull@russopartnersllc.com

858.717.2310

 

SOURCE Arena Pharmaceuticals, Inc.

A new approach to treating osteoarthritis

January 20, 2015 – 12:31 pm | Edit Post

Researchers design a nanoparticle that improves delivery of anti-osteoarthritis drugs

A new approach to treating osteoarthritis

January 20, 2015 – 12:31 pm | Edit Post

Researchers design a nanoparticle that improves delivery of anti-osteoarthritis drugs

MS patients given stem cells improve

January 20, 2015 – 9:22 am | Edit Post

Multiple sclerosis patients improved with stem cell therapy, a preliminary study finds.

MS patients given stem cells improve

January 20, 2015 – 9:22 am | Edit Post

Multiple sclerosis patients improved with stem cell therapy, a preliminary study finds.

Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene’s Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients

January 20, 2015 – 6:15 am | Edit Post
Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene’s Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients

Trovagene’s proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis

SAN DIEGO, Jan. 20, 2015 /PRNewswire/ — Trovagene, Inc., (NASDAQ:  TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical studies at the 2015 Gastrointestinal Cancer Symposium (also known as ASCO GI) held in San Francisco, CA. Results demonstrate the ability of the Company’s Precision Cancer MonitoringSM platform to detect and quantitate KRAS mutations at diagnosis and longitudinally in cell-free DNA (cfDNA) obtained from colorectal and pancreatic cancer patients.

Poster #1: Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations

In this study, archived, matched plasma and urine samples, stored between 3-5 years prior to circulating tumor DNA extraction, from 20 Stage I-IV colorectal cancer patients with known KRAS mutations in tumor tissue were used in a retrospective setting for a blinded pilot study. The majority of patients in the study underwent surgery for primary tumor and/or liver metastases and received neo-adjuvant or adjuvant therapy. Trovagene’s platform technology, specifically its quantitative KRAS mutation assay, was used to analyze patient specimens and compare KRAS mutational status in urine, blood, and tissue samples, and to monitor KRAS burden in response to therapy.

Results showed high concordance in KRAS detection between plasma and tissue, and between urine and tissue. Dynamic changes in KRAS mutational burden were highly correlated to response from both surgical and chemotherapeutic treatment.

“By tracking the mutational status of advanced colorectal cancer patients post-surgery, clinicians can rapidly determine the surgery outcome and monitor the effectiveness of a subsequent therapy,” said study investigator, Lucie Benesova, Ph.D., science director at the Center for Applied Genomics of Solid Tumors, Genomac Research Institute in Prague, Czech Republic. “Trovagene’s assay has potential to provide this information, which can be critical in selecting the best follow up care for patients that have undergone this procedure.”

Poster #2: Comparative circulating tumor DNA levels for KRAS mutations in patients with non-resectable pancreatic cancer

The Danish BIOPAC study evaluated different chemotherapy regimens for the treatment of pancreatic cancer. From this study, archived blood samples from 182 non-resectable pancreatic cancer patients with 600 longitudinal samples, were tested qualitatively and quantitatively for KRAS mutational status. KRAS mutations are present in the vast majority of pancreatic tumors, and the study’s objective was to determine to what extent monitoring of KRAS mutations from circulating tumor DNA (ctDNA) can be used to predict overall survival (OS).

Results demonstrated that different levels of KRAS mutations at diagnosis can predict patient outcome and may reflect distinct underlying tumor biology. The data also demonstrated that patients with high levels of KRAS mutations at diagnosis, as well as elevated KRAS mutation load post-treatment, were associated with shorter overall survival times. Longitudinally, low KRAS mutation load correlated with long OS.

“Results of this study validate that high KRAS mutation levels at diagnosis, as well as increases in mutational load over time, significantly correlate with poor prognoses for patients diagnosed with pancreatic cancer,” stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. “Trovagene’s assay for KRAS mutant oncogenes can assist physicians in determining the aggressiveness of a patient’s disease, and provide useful information such that therapy may be tailored accordingly.”

About The Role of KRAS Mutations In the Diagnosis and Treatment of Colorectal Cancer

Somatic KRAS mutations are found at high rates in patients diagnosed with colon cancer, pancreatic cancer, lung cancer, and leukemias. In metastatic colorectal cancer, a number of large studies have shown that EGFR-inhibiting drugs, such as cetuximab (Erbitux®) and panitumumab (Vectibix®), can be significantly effective in patients with KRAS wild-type (non-mutant) tumors. In the Phase III CRYSTAL study, published in 2009, patients with the wild-type KRAS gene treated with Erbitux® plus chemotherapy showed a response rate of up to 59% compared to those treated with chemotherapy alone. Patients with the KRAS wild-type gene also showed a 32% decrease in the risk of disease progression compared to patients receiving chemotherapy alone. Conversely, KRAS mutations are highly predictive of a poor response to these drugs in the treatment of colorectal cancer. Currently, the most reliable way to predict whether a colorectal cancer patient will respond to one of the EGFR-inhibiting drugs is to test for certain “activating” mutations in the gene that encodes KRAS, which occurs in 30%-50% of colorectal cancers. Studies show patients whose tumors express the mutated version of the KRAS oncogene will not respond to cetuximab or panitumumab. Importantly, the emergence of KRAS mutations is a frequent driver of acquired resistance to anti-EGFR therapy in colorectal cancers. Therefore, monitoring patients for the emergence of KRAS mutant clones prior to the detection of progression using radiographic scans can be critical for determining early resistance and for the reassessment of therapy in this clinical situation. Clinical research suggests that early initiation of a MEK inhibitor can be a rational strategy for delaying or reversing drug resistance due to the emergence of KRAS mutations.

About The Prevalence of KRAS Mutations in Pancreatic Cancer

Pancreatic cancer is considered to be one of the most deadly cancers due to its aggressive nature and advanced stage at diagnosis. The American Cancer Society estimates that 44,220 people in the United States will be diagnosed with pancreatic cancer and about 38,460 will die from the disease. An estimated 80 percent of pancreatic cancer patients have non-resectable or metastatic disease, and upwards of 95 percent of pancreatic cancers are estimated to harbor KRAS mutations. Based on these statistics, the need for an accurate, cost-effective test to quantify and monitor KRAS mutational status is high.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Ian Stone

Account Director

Trovagene, Inc.

Canale Communications, Inc.

858-952-7593

619-849-5388

ir@trovagene.com

ian@canalecomm.com

Logo – http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

SOURCE Trovagene, Inc.

Tauriga Sciences Inc. Appoints Hingge Hsu, M.D., M.B.A. to its Board of Directors

January 20, 2015 – 6:00 am | Edit Post
Tauriga Sciences Inc. Appoints Hingge Hsu, M.D., M.B.A. to its Board of Directors

LOS ANGELES, Jan. 20, 2014 /PRNewswire/ — Tauriga Sciences, Inc. (OTCQB: TAUG) or (“Tauriga” or “the Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced the appointment of Hingge Hsu, M.D., M.B.A. to its Board of Directors. Dr. Hingge Hsu was recently a Partner at Fidelity Biosciences and was on the core healthcare investment team for Fidelity Growth Partners Asia. He was previously a Managing Director at Lehman Brothers in their Private Equity Group, responsible for their principal investment activities in the private and public sectors of the healthcare industry. Dr. Hsu has structured and led numerous transactions in the life science sector, and he has been instrumental in building and growing his portfolio companies. In addition, Dr. Hsu has held operating positions at Chiron Corporation and Gensia, Inc. in the areas of business development and strategic planning. Dr. Hsu strengthens the Tauriga Board of Directors with his venture capital and investment banking experience, technical and industry knowledge, and an extensive network in both the U.S. and Asia.  Moreover, he has personally invested in Tauriga Sciences based on his confidence in their strategic plan.

Tauriga’s Chairman and CEO Dr. Stella M. Sung stated, “I am pleased to have Dr. Hingge Hsu join our Board of Directors at this pivotal time, as we begin to generate revenues from our newly launched natural wellness business and grow our company on a global level. Tauriga has recently expanded its investor base to Asia, and we have developed relationships with iFlow, Dragoon Capital and other Asian companies. Dr. Hsu’s transactional and business development expertise and his understanding of Asian markets will be invaluable to Tauriga. His proven ability to commercialize new technologies and create new market opportunities are applicable to both of Tauriga’s key businesses: Pilus Energy’s synthetic biology approach to ‘wastewater to value’ and Tauriga’s natural wellness product line consisting of dietary supplements and of creams and soft gels using CBD oil extracted from industrial hemp.”

Dr. Hingge Hsu commented, “I look forward to using my strategic and transactional experience to help Tauriga grow its business opportunities and geographical reach. I have evaluated the new Tauriga supplements now available on www.taurigastore.com, and I personally believe they address important health needs and can promote wellness and improve overall quality of life. I have enjoyed working with Dr. Sung in the past and look forward to assisting her and the entire Tauriga management team and Board of Directors in building a valuable company based on strong fundamentals.”

Prior to his positions at Fidelity and Lehman, Dr. Hsu was a Partner at Schroder Ventures Life Sciences from 1998 to 2001 and directed their US investment activities in the life sciences and therapeutics sectors. He received an MD degree from Yale University School of Medicine and was trained in internal medicine at Brigham and Women’s Hospital and Harvard Medical School. Dr. Hsu also received an MBA degree from Harvard Business School. Dr. Hsu previously has served on a number of Board of Directors, including most recently that of NextWave Pharmaceuticals and Fluidnet (now known as Ivenix).

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.

NON SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

SOURCE Tauriga Sciences, Inc.

Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015

January 20, 2015 – 6:00 am | Edit Post
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015

SAN DIEGO, Jan. 20, 2015 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society’s 97th Annual Meeting. ENDO is the world’s largest endocrinology meeting drawing over 10,000 experts from around the world.  The ENDO 2015 meeting will be held in San Diego from March 5-8, 2015.

“We are pleased to have been selected to hold an oral presentation at the annual meeting of the Endocrine Society and to share the clinical data of NBI-77860 in classic congenital adrenal hyperplasia with the broader scientific community,” said Chris O’Brien, M.D., Chief Medical Officer at Neurocrine. “Congenital adrenal hyperplasia is a disease with a significant unmet medical need and NBI-77860 may potentially make an important difference in patients’ lives. The ENDO annual meeting brings together the world’s thought leaders in endocrinology to discuss the latest advances in the field and we look forward to discussing our clinical results at this meeting.”

The oral presentation of the results from the initial clinical study of NBI-77860 for the treatment of classic congenital adrenal hyperplasia will occur at the 97th Annual Meeting of the Endocrine Society on Thursday, March 5, 2015 from 11:30 am to 1:00 pm (PST). The session is entitled “HPA Axis and Adrenal: Receptors to Clinical Impact.”

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine’s business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company’s R & D pipeline including risk that the Company’s clinical candidates will not be found to be safe and effective; and the other risks described in the Company’s report on Form 10-K for the year ended December 31, 2013 and on Form 10-Q for each of the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 

SOURCE Neurocrine Biosciences, Inc.

Biocept, Inc. Introduces New Test For Patients With Non-Small Cell Lung Cancer

January 19, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 20, 2015 (GLOBE NEWSWIRE) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis…